1. A Lipid‐Sensitive Spider Peptide Toxin Exhibits Selective Anti‐Leukemia Efficacy through Multimodal Mechanisms
- Author
-
Peng Zhang, Wu Luo, Zixin Zhang, Mingchong Lv, Longkang Sang, Yuhan Wen, Lingxiang Wang, Changhao Ding, Kun Wu, Fengjiao Li, Yueqi Nie, Jiaoyue Zhu, Xiaofeng Liu, Yan Yi, Xiaofeng Ding, Youlin Zeng, and Zhonghua Liu
- Subjects
anticancer peptide ,apoptosis ,cell cycle arrest ,ferroptosis ,leukemia ,PI3K‐AKT‐mTOR signaling pathway ,Science - Abstract
Abstract Anti‐cancer peptides (ACPs) represent a promising potential for cancer treatment, although their mechanisms need to be further elucidated to improve their application in cancer therapy. Lycosin‐I, a linear amphipathic peptide isolated from the venom of Lycosa singorensis, shows significant anticancer potential. Herein, it is found that Lycosin‐I, which can self‐assemble into a nanosphere structure, has a multimodal mechanism of action involving lipid binding for the selective and effective treatment of leukemia. Mechanistically, Lycosin‐I selectively binds to the K562 cell membrane, likely due to its preferential interaction with negatively charged phosphatidylserine, and rapidly triggers membrane lysis, particularly at high concentrations. In addition, Lycosin‐I induces apoptosis, cell cycle arrest in the G1 phase and ferroptosis in K562 cells by suppressing the PI3K‐AKT‐mTOR signaling pathway and activating cell autophagy at low concentrations. Furthermore, intraperitoneal injection of Lycosin‐I inhibits tumor growth of K562 cells in a nude mouse xenograft model without causing side effects. Collectively, the multimodal effect of Lycosin‐I can provide new insights into the mechanism of ACPs, and Lycosin‐I, which is characterized by high potency and specificity, can be a promising lead for the development of anti‐leukemia drugs.
- Published
- 2024
- Full Text
- View/download PDF